Fig. 3From: Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type IbAbsolute neutrophil count, G-CSF dose and empagliflozin dose over the time of treatment. a Absolute neutrophil count. b) G-CSF and empagliflozin dose. The G-CSF dose was reduced stepwise and G-CSF could be discontinued after 26 years of treatment on day 41 on empagliflozinBack to article page